Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New 3D test system for breast cancer radiosensitizing drugs

23.06.2015

Radiation therapy is an important part of breast cancer treatment. Sometimes, however, tumor cells become increasingly resistant to radiation damage. Now, scientists of Helmholtz Zentrum München have developed a 3D microtissue-based screening system which, for the first time, enables them to test which chemotherapeutic drugs can resensitize breast cancer cells to radiation.

The team of researchers led by Dr. Nataša Anastasov, head of the research group ‘Personalized Radiation Therapy’ at the Institute of Radiation Biology, created multicellular three-dimensional spheroids containing a mix of breast cancer cells and connective tissue cells.


Picture: Hanging Drop System for the production of 3D micro tissue

Source: InSphero AG (2014)

As Anastasov explained, “In conventional cell culture, cell growth is two dimensional, which does not adequately reproduce the characteristics of a tumor in the living organism.” Using the new screening system, the scientists can treat the cancer cells both with various chemical compounds and with radiation to determine the effects – and that in 3D.

In their study the researchers collaborated closely with the ‘Assay Development and Screening Platform’ at Helmholtz Zentrum München and the Munich-based Sirion Biotech GmbH and the Swiss InSphero AG.

The trick: fluorescent cells in hanging drops

“In our system, up to 96 wells containing microtissue spheroids can be simultaneously monitored by a computer,” said co-author Dr. Ines Höfig, explaining the fundamental principle. “For this purpose, the 3D-microtissue spheroids were grown in a hanging drop culture on the underside of a special perforated plate. After a few days, these were transferred onto an assay plate.”

Her colleague Vanja Radulović added: “Because the breast tumor cells and the connective tissue cells have been labeled with different fluorescent markers, they fluoresce in different colors. A software program can thus capture precisely how each of the spheroids reacts to the treatment.”

To confirm their method, the scientists tested the properties of several drugs which are already used in tumor therapy. The drug vinblastine proved to be the most effective in combination with radiation. In the future, the researchers plan to expand their system by adding other components of the tumor environment such as stromal or immune cells in order to optimally simulate the situation in the patient.

Prof. Dr. Michael Atkinson, director of the Institute of Radiation Biology, views the findings of his colleagues with optimism: “For the first time a convenient 3D test for high throughput screening is available with which new drug compounds developed to resensitize tumor cells to radiation treatment can be tested. This will speed up future initiatives for drug development and will also enable the screening of established drugs in combination with radiation.”


Further Information

Background:
The rapid evolution of resistance to both conventional and small molecule therapies is a challenging problem in oncology. One approach to overcome resistance is to use combinatorial treatments that exploit their synergies. The combination of chemotherapy and radiation treatment is a potentially effective combinatorial procedure, although the optimal mix has not been identified. A major drawback in identifying potentially radiation-sensitizing active agents is the lack of high throughput screening (HTS) vehicles. These are needed to replace conventional clonogenic survival assays of radiation treatment as these are too time consuming to operate in a first-pass screening mode. Moreover, there are growing concerns that monolayer and monotypic cellular screening assays may not effectively reproduce the response of a three-dimensional solid tumor to pharmacological compounds.

Original Publication:
Anastasov, N. et al. (2015). A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment, BMC Cancer, DOI: 10.1186/s12885-015-1481-9

As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The research of the Institute of Radiation Biology (ISB) focuses on understanding the effects of low dose radiation exposure and on studies to increase the effectiveness and specificity of tumor radiotherapy. The research program is carried out by four interlinked research groups. The ISB is part of the Department of Radiation Sciences (DRS).

Contact for the media:
Department of Communication, Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49-(0)89-3187-2238 - Fax: +49 89-3187-3324 - Email: presse@helmholtz-muenchen.de

Scientific contact at Helmholtz Zentrum München:
Dr. Nataša Anastasov, Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49-(0)89-3187-3798 - Fax: +49-(0)89-3187-3378 - E-Mail: natasa.anastasov@helmholtz-muenchen.de

Weitere Informationen:

http://www.helmholtz-muenchen.de/en/index.html - Website Helmholtz Zentrum München
http://www.helmholtz-muenchen.de/en/isb/index.html - Website Institute of Radiation Biology
http://www.helmholtz-muenchen.de/aktuelles/pressemitteilungen/2015/index.html - Press Releases of the Helmholtz Zentrum München

Helmholtz Kommunikation | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>